The pharmacological basis for the treatment of photodermatoses.
The pharmacological basis for the treatment of photosensitivity diseases is poorly understood. The supposed pathogenesis of photosensitivity reactions is reviewed, and the mechanism of action of drugs known to be efficient in this type of reaction (antimalarials, beta-carotene, thalidomide, PUVA therapy) discussed.
D000941:Antigens / Q000276:immunology / Q000528:radiation effects; D000962:Antimalarials / Q000494:pharmacology / Q000627:therapeutic use; D002338:Carotenoids / Q000494:pharmacology / Q000627:therapeutic use; D004247:DNA / Q000378:metabolism; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D008297:Male; D009536:Niacinamide / Q000172:deficiency; D011701:PUVA Therapy; D010383:Pellagra / Q000188:drug therapy / Q000209:etiology; D010787:Photosensitivity Disorders / Q000188:drug therapy* / Q000276:immunology; D011164:Porphyrias / Q000188:drug therapy / Q000209:etiology; D011166:Porphyrins / Q000378:metabolism*; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology; D013472:Sunlight / Q000009:adverse effects; D013601:T-Lymphocytes / Q000276:immunology; D013792:Thalidomide / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014466:Ultraviolet Rays; D014575:Uroporphyrinogen Decarboxylase / Q000378:metabolism; D014578:Uroporphyrins / Q000378:metabolism; D014581:Urticaria / Q000188:drug therapy / Q000209:etiology; D019207:beta Carotene
D000941:Antigens; D000962:Antimalarials; D011166:Porphyrins; D014578:Uroporphyrins; D019207:beta Carotene; D009536:Niacinamide; D002338:Carotenoids; D013792:Thalidomide; D004247:DNA; D014575:Uroporphyrinogen Decarboxylase